新兴体_外诊断市场_寻求中_国下一阶段的增长（英文版）_9页_3mb

Emerging In-vitro Diagnostics (IVD) Markets in China: Summary

Core Content

The report by The Economist Intelligence Unit (EIU) provides an in-depth analysis of the growth of the IVD market in China and the increasing competitiveness of domestic IVD companies. It highlights the opportunities and challenges in expanding IVD businesses into emerging markets, offering strategic insights for both multinational and local players.

Key Market Trends

• China's IVD Market:

  • China is the largest IVD market in Asia-Pacific, accounting for over 50% of the region's total market.
  • The market is projected to grow at more than 10% annually from 2017 to 2022.
  • Growth is driven by the expansion of next-generation sequencing and molecular diagnostics, despite pressure on test prices from new reimbursement schemes.

• Growth Drivers:

  • Immunodiagnostics: Expected to be the fastest-growing segment in centralised diagnostics (CDx), with critical care, fertility, and bone health as the top three sub-segments.
  • Point-of-Care (POC) Diagnostics: Growth is fueled by an aging population and increased patient access to care in near-patient settings. The top three sub-segments include connected blood glucose testing in hospitals, coagulation, and cardiac testing.
  • Molecular Diagnostics (MDx): Expected to see growth due to new clinical guidelines and an increasing number of approved testing parameters. Genomics, oncology (specifically HPV and next-generation sequencing), and microbiology (CT/NG) are the fastest-growing areas.
  • Tissue Diagnostics (TDx): Increasing automation in H&E staining and the opening of regional pathology centres are driving demand for workflow solutions and digital pathology. The top three sub-segments are special stains, immunohistochemistry (IHC) reagents, and H&E staining.

Domestic IVD Companies: Growth and Strategies

• Market Share Growth:

  • Domestic companies have captured 15% of the CDx market in 2012 and 21% by 2017.
  • They are also gaining significant traction in POC, MDx, and TDx markets.

• Strategic Advantages:

  • Autobio (AnTu Bio): One of the fastest-growing companies in immunodiagnostics, with strong R&D investment and a dedicated cardiac business.
  • Getein Biotech (JiDeng Bio): A leading player in POC diagnostics, particularly in cardiac testing.
  • AmoyDx (AiDe Bio): A top player in oncology tests, with a wide range of CFDA-approved MDx products.
  • Hytribio: Rapidly expanding in MDx, especially in HPV screening and sub-typing, and using its IPO funds to strengthen its distribution network and R&D capabilities.

Expansion into Other Emerging Markets

• Mindray (the largest domestic IVD company in China) is expanding into Asia, Latin America (LATAM), and the Middle East and Africa (MEA).
  • In Indonesia, it has captured 12% of the clinical chemistry market.
  • In LATAM, it holds 11% in Colombia and 8% in Peru.
• Other domestic companies are also making inroads into these markets, indicating a shift in the competitive landscape.

IVD Gateway: Strategic Insights for Emerging Markets

• Country-Level Insights: Understanding macro-environmental factors, policies, healthcare systems, disease burden, and infrastructure is crucial for accessing fast-growing emerging markets.
• Segment-Level Insights: Detailed analysis of demand in IVD segments helps companies identify unpenetrated opportunities and anticipate trends.
• Competitor Insights: Monitoring the strategies and operations of 60+ market players enables companies to develop differentiated growth strategies.
• Customer Insights: Analyzing the needs of different customer segments, such as public and private hospitals, commercial labs, and blood banks, is essential for aligning products and services with market demands.

Conclusion

The IVD market in China is experiencing robust growth across multiple segments, with domestic companies increasingly capturing market share and expanding into other emerging markets. Strategic R&D investment, cost-effective solutions, and strong government partnerships are key factors behind this growth. For companies looking to enter or expand in these markets, IVD Gateway offers comprehensive insights to support informed business decisions.